In semiconductor packaging, avoiding product warpage is difficult since it involves product specifications and related processes. In order to effectively predict warpage, traditional methods use a ...

Verrica’s product YCANTH ® (VP-102) (cantharidin), is the first and only commercially available treatment approved by the FDA to treat adult and pediatric patients two years of age and older with ...

Asahi Kasei Pharma has started trial drug administration in a Phase III study of ART-123 in Japan (generic name: thrombomodulin alfa; marketed as Recomodulin™ Injection in Japan) for the prevention of ...

FineHeart Receives Slovenia JAZMP (Agency for Medicinal Products and Medical Devices of the Republic of Slovenia) Authorization to Launch Its FIH Clinical Study on Patients Suffering From Advanced ...

Verrica Pharmaceuticals Announces Amendment to Collaboration and License Agreement with Torii Pharmaceutical to Launch Global Pivotal Phase 3 Clinical Trial to Study ...

Teva Pharmaceutical Industries Ltd. announced the final analysis of the PEARL Phase 4 study at the European Academy of Neurology Congress 2025, confirming that AJOVY (fremanezumab) is effective in ...

Verona Pharma's Ohtuvayre launch drives rapid growth and global expansion. Read about the VRNA stock's Q1 results, analyst insights, and future rally potential.